Morocco: These 6 Drugs Face Patent Expirations and Generic Entry in 2025 - 2026

Generic name: suvorexant
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 01, 2026
Generic Entry Controlled by: Morocco Patent 31,016

BELSOMRA is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.

This drug has seventy-five patent family members in thirty-six countries.

See drug price trends for BELSOMRA.

The generic ingredient in BELSOMRA is suvorexant. One supplier is listed for this generic product. Additional details are available on the suvorexant profile page.

Generic name: amlodipine besylate; hydrochlorothiazide; valsartan
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 27, 2026
Generic Entry Controlled by: Morocco Patent 30,529

EXFORGE HCT is a drug marketed by Novartis. There has been litigation on patents covering EXFORGE HCT

See drug price trends for EXFORGE HCT.

The generic ingredient in EXFORGE HCT is amlodipine besylate; hydrochlorothiazide; valsartan. There are fifty drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the amlodipine besylate; hydrochlorothiazide; valsartan profile page.

Generic name: amlodipine besylate; perindopril arginine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 28, 2026
Generic Entry Controlled by: Morocco Patent 30,276

PRESTALIA is a drug marketed by Adhera. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty patent family members in twenty-seven countries. There has been litigation on patents covering PRESTALIA

The generic ingredient in PRESTALIA is amlodipine besylate; perindopril arginine. There are fifty drug master file entries for this API. Additional details are available on the amlodipine besylate; perindopril arginine profile page.

Generic name: vortioxetine hydrobromide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 16, 2026
Generic Entry Controlled by: Morocco Patent 30,575

TRINTELLIX is a drug marketed by Takeda Pharms Usa. There are ten patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering TRINTELLIX

See drug price trends for TRINTELLIX.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the vortioxetine hydrobromide profile page.

Generic name: vorinostat
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 23, 2026
Generic Entry Controlled by: Morocco Patent 28,209

ZOLINZA is a drug marketed by Msd Sub Merck. There are four patents protecting this drug.

This drug has one hundred and thirty-one patent family members in thirty-five countries.

See drug price trends for ZOLINZA.

The generic ingredient in ZOLINZA is vorinostat. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the vorinostat profile page.